Objectives: Percutaneous kidney biopsy is a useful diagnostic procedure. Hemorrhagic complications may occur following the procedure. Methods: We retrospectively analyzed the records of 1198 patients who had percutaneous renal biopsy between March 2013 and March 2018. The cohort included both native kidney and transplant biopsies. We have included only the first biopsy for each patient; repeat biopsies for 132 patients were excluded from the analysis. Results: 1198 patients ( 332 transplant recipients and 886 native kidney patients) were included in the study. Major complications occurred in 18(1.5%) of patients (1.4% in native kidney biopsies Vs 1.6% in kidney transplant recipients. Adequate renal tissue (core of > 6 glomeruli ) was obtained in 91 % of patients. Our analysis revealed that the incidence of major complications, in the native kidney biopsy are increased with age>65 years (odds ratio2.4, 95 % CI (1.5-5.6), eGFR<30 ml/min/m2 (odds ratio 9.7, 95 % CI (3.4-18.2) ) and anemia(9-11 mg/dl)(odds ratio3.2 (1.7-5.2), 95 % CI(1.7-5.2). In transplant recipients kidney biopsy the incidence of complications was increased with age>65 years (odds ratio 2.8(1.7-7.3), 95 % CI (1.7-7.3), eGFR<30 ml/min/m2 (odds ratio 11.3, 95 % CI (3.5-16.8 ) and anemia (9-11mg/dl )(odds ratio 2.4, 95 %(1.7-4.7). Conclusion: The incidence of major complications following kidney biopsy was 1,5%(for a cohort of native kidney biopsy and kidney transplant biopsies . Age> 65 years, lower eGFR < <30 ml/min/m2 and anemia were independent risk predictors for the occurrence of major complications in both native and transplant kidney biopsy.
Keywords: Biopsy; biopsy, needle; renal, complications, safety, adequacy.
Background: Cardiovascular disease is a major cause of morbidity and mortality in hemodialysis patients, there is increasing evidence that platelets are major contributors to atherosclerosis, which is mediated through F11 receptors. Methods: Our study included 40 hemodialysis patients divided into two groups: Group 1: included 20 hemodialysis patients with ischemic heart disease (IHD), Group 2: included 20 hemodialysis patients without ischemic heart disease, they were compared with 20 age and sex matched controls, soluble F11 receptor (sF11R) and high sensitivity C-reactive protein (hs-CRP) were measured by enzyme-linked immunosorbent assay (ELISA). Results: sF11R was significantly higher in hemodialysis patients than controls; it showed significant difference between group 1, group 2 patients and controls. sF11R showed significant positive correlation with hs-CRP. Conclusion: sF11R can be considered a marker of IHD in hemodialysis patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.